Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.


Top 3 Must Do's to Prepare for Managed Care in 2016

March 24th 2016

Although there still are many unknowns, especially in light of this being an election year that will bring a new administration, it’s already very clear how the transition to value is affecting oncology practices.

Eribulin Liposarcoma Approval Advances Precision Medicine in Oncology

March 23rd 2016

George Demetri, MD, discusses the impact of the eribulin’s FDA approval, what oncologists can learn from studying liposarcoma, and the challenges that come with treating a rare disease.

Combined Biomarker Score Is Better Survival Predictor in Ovarian Cancer

March 20th 2016

Combining 3 markers of homologous recombination deficiency significantly improved prediction of outcome of platinum-based treatment of ovarian cancer compared with the individual markers, a retrospective analysis of tissue samples showed.

Expanded Indication Sought for Ofatumumab in CLL

March 15th 2016

A supplemental new drug application has been submitted to the FDA for ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia.

FDA Approves Crizotinib for ROS1-Positive NSCLC

March 11th 2016

The FDA has approved crizotinib as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.

FDA Accepts Application to Expand Pembrolizumab NSCLC Indication

March 7th 2016

The FDA has accepted a supplemental new drug application for pembrolizumab as a treatment for patients with advanced non–small cell lung cancer with PD-L1 expression on ≥1% of tumors cells.

FDA Approval Sought for Blinatumomab in Pediatric Acute Lymphoblastic Leukemia

March 3rd 2016

A supplemental biologics license application has been submitted to the FDA to expand the approval of blinatumomab (Blincyto) to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Alaskan Oncology Practices Operate by Remote

March 3rd 2016

Obtaining quality cancer care in Alaska is often difficult and expensive owing to the sparse highway network and the scattered nature of the state’s population of 736,000 people, who are spread out over more than a half-million square miles.

FDA Approves Everolimus for GI, Lung NETs

February 26th 2016

The FDA has approved everolimus for the treatment of adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal or lung neuroendocrine tumors.

FDA Approves Obinutuzumab for Follicular Lymphoma

February 26th 2016

The FDA approved obinutuzumab (Gazyva) plus bendamustine followed by obinutuzumab alone for the treatment of patients with follicular lymphoma who were not responsive to a rituximab regimen, or who relapsed after rituximab-based therapy.

FDA Agrees to Review Supplemental NDA for Enzalutamide in Metastatic Prostate Cancer

February 23rd 2016

The FDA has accepted, for review, a supplemental new drug application for enzalutamide (Xtandi) capsules in patients with metastatic castration-resistant prostate cancer that includes findings from the head-to-head studies, TERRAIN and STRIVE.

Hatch-Waxman Act Keeps Generic Drugs Off the Market

February 22nd 2016

The Hatch Waxman Act, established in 1984 to promote lower cost generics production, is deeply flawed and has contributed to the maintenance of high drug prices.

FDA Grants Midostaurin Breakthrough Designation for AML

February 19th 2016

The FDA has granted midostaurin a breakthrough therapy designation as a potential treatment for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia.

Durvalumab Granted Breakthrough Status for Bladder Cancer

February 17th 2016

The FDA has granted a breakthrough therapy designation to durvalumab as a treatment for patients with PD-L1–positive inoperable or metastatic urothelial bladder cancer following progression on prior treatment with a platinum-based regimen.

Second Partnership Was the Charm for Seattle Oncology Practice

February 14th 2016

For one group of physicians in Seattle, hooking up with US Oncology seemed like a good idea at first, until circumstances changed and the deal no longer was a benefit for any of the partners.

FDA Places Pacritinib on Full Clinical Hold

February 13th 2016

The FDA has placed a full clinical hold on trials exploring pacritinib, following reports of patient deaths related to intracranial hemorrhage, cardiac failure, and cardiac arrest in the phase III PERSIST-2 trial.

Bankruptcy in Cancer Survivors

February 13th 2016

Matthew Banegas, PhD, MPH, discusses a recent study that found that a considerable number of working-age adults who survive cancer and its toxic treatments, end up with substantial medical debts or declare bankruptcy.

FDA Schedules ODAC Meeting for Rociletinib in NSCLC

February 12th 2016

The FDA has scheduled an ODAC advisory hearing for April 12, 2016, to discuss the new drug application for rociletinib as a treatment for patients with metastatic EGFR T790M-mutated non–small cell lung cancer.

Cautious Evolution Underway in DTC Genetic Testing

February 12th 2016

Changes are brewing again in the direct-to-consumer genetic testing industry including developments with the potential to affect the public in the oncology field.

FDA Grants T-Cell Therapy Breakthrough Designation in Sarcoma

February 9th 2016

An affinity enhanced T-cell therapy has received an FDA breakthrough therapy designation for the treatment of patients with inoperable or metastatic pretreated synovial sarcoma who harbor HLA-A*201, HLA-A*205, or HLA-A*206 alleles and whose tumors express the NY-ESO-1 tumor antigen.

NEXT PAGE
PREVIOUS PAGE